We found that the combination treatment of an XPO1 inhibitor (selinexor) and a PI (bortezomib) synergistically increased IκBα more than single-agent selinexor or bortezomib treatment in both parental and PI-resistant MM cell lines and in patient myeloma cells. Here, XPO1 is linked to Miyoshi myopathy.